Skip to main navigation
Skip to main content
Skip to Footer
US
Sandoz Site Directory
Home
Our Work
What We Do
Disease Areas
Quality Generics
Biosimilars
Partnerships and Collaborations
Access to Healthcare
About Us
Who We Are
Corporate Responsibility
For Novartis Investors
Contact Us
Doing Business Responsibly
Patients & Customers
Report Side Effects
Product Safety Notices
Information for Customers
Products
News
US Press Releases & News
Media Contacts
Publications
Careers
Job Search
Working at Sandoz US
Diversity & Inclusion
Search
All News
Advanced Search
Basic Search
From Date:
To Date:
Show:
All
Featured News
Media Releases
In the News
Filter By
2020
March
Media Release
/
Mar 29, 2020
Novartis donation: Consignment of 30 million hydroxychloroquine tablets ships to US Department of Health and Human Services
Read More
Media Release
/
Mar 23, 2020
Sandoz acquires US distribution rights to two key hospital injectable medicines, reinforcing strategic focus on key growth segment
Read More
Media Release
/
Mar 20, 2020
Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response
Read More
Media Release
/
Mar 02, 2020
Sandoz Resolves Generic Drug Antitrust Investigation in the U.S.
Read More
February
Media Release
/
Feb 06, 2020
AAM names Carol Lynch, Vice Chair of the Board
Read More
2019
November
Media Release
/
Nov 05, 2019
Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar Ziextenzo™ (pegfilgrastim-bmez)
Read More
Media Release
/
Nov 04, 2019
Sandoz lowers Glatopa® (glatiramer acetate injection) price in US to offer people with MS high-quality care at a more affordable price
Read More
October
Media Release
/
Oct 15, 2019
Sandoz and Pear Therapeutics announce Pear will solely commercialize reSET® and reSET-O®
Read More
September
Media Release
/
Sep 23, 2019
Sandoz Inc. Issues Voluntary Recall of Ranitidine Hydrochloride Capsules 150mg and 300mg Due to an Elevated Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA), in the Product
Read More
Media Release
/
Sep 05, 2019
Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine
Read More
Search Results Navigation
First page
« first
Previous page
‹ previous
…
Page
2
of 5
Page
3
of 5
Current page
4
of 5
Page
5
of 5
Page
6
of 5
…
Next page
next ›
Last page
last »
Twitter
Tweet
Facebook
Share
Share
Twitter
Facebook
LinkedIn
Email
Jump to Comments
Print
Save
You are here
Home
›
News
›